U.S., Dec. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07272109) titled 'Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes' on Nov. 26.
Brief Summary: The purpose of this study is to evaluate the efficacy of anti-diabetic treatment on improving the overall survival for metastatic pancreatic cancer patients complicated by diabetes receiving gemcitabine and nab-paclitaxel chemotherapy.
Study Start Date: Jan. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Intervention:
DRUG: Nab-paclitaxel
120 mg per square meter of body-surface area on days 1, 8, and 15 every 4 weeks
DRUG: Gemcitabine (1000 mg/m2)
(1000 mg per square meter) on days 1, 8, and ...